Single-center, open, non-randomized, single-arm clinical trial of donor CD7-CAR T cells in the treatment of refractory/relapsed acute T-lymphocytic leukemia in children
Latest Information Update: 01 Jul 2022
At a glance
- Drugs Anti-CD7 chimeric antigen receptor T cell therapy-Yake Biotechnology (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
Most Recent Events
- 07 Jun 2022 Results of updated safety and efficacy presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 06 Aug 2021 New trial record
- 29 Jul 2021 Results published in the Journal of Clinical Oncology